ProQR Therapeutics NV (NASDAQ:PRQR) has been upgraded to Hold in a report by Zacks Investment Research today.
- Updated: September 22, 2016
Zacks Investment Research has upgraded ProQR Therapeutics NV (NASDAQ:PRQR) to Hold in a report released on 09/23/2016.
Yesterday ProQR Therapeutics NV (NASDAQ:PRQR) traded 5.14% higher at $6.81. The company’s 50-day moving average is $5.65 and its 200-day moving average is $5.12. The last closing price is up 39.94% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 94,726 shares of the stock traded hands, up from an average trading volume of 22,958
See Chart Below
ProQR Therapeutics NV has a 52 week low of $3.48 and a 52 week high of $20.05 ProQR Therapeutics NV’s market capitalization is presently $0.
A total of 3 brokerages have issued a ratings update on ProQR Therapeutics NV. zero brokerages rating the company a strong buy, zero brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $22.67.
General Company Details For ProQR Therapeutics NV (NASDAQ:PRQR)
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010 and QR-110. It is focusing on developing QRX- 911, QRX- 021, QRX- 313, QRX- 704, QRX- 812, QRX- 411, QRX- 504, QRX- 604 and QRX- 203. QR-010 is an RNA-based oligonucleotide. QR-110, is an oligonucleotide.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.